Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
NCT Number:
NCT05327686
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Kidney
Study Objectives:
To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma (RCC). The primary endpoint is nephrectomy and radiographic progression-free survival (nrPFS) with progression determined as per iRECIST criteria.
Study Documents
(MUSC NetID required for document access)